09 nov: USA/Fed: Udsigterne til et renteløft i december styrtdykker
09 nov: Zealand Pharma Q3: Lavere omkostninger bag opjustering
09-11-2016 07:41:02

Bavarian Nordic Announces Interim Results for the First Nine Months of 2016

Relateret indhold
22 jun - 
Bavarian skærer 39 stillinger fra ved hovedkvarteret
19 jun - 
Mandagens aktier: FLSmidth og Danske Bank førte an i fr..
19 jun - 
Aktier/middag: FLSmidth og Genmab styrer C20 mod rekord
Relateret debat
18:01 - 
Anekdotisk evidens. Og her siger han at den muligvis ka..
17:58 - 
Lad nu ham Mr. World leve i sin egen drømmeverde..
17:09 - 
Forfærdeligt luk dagens laveste. Mr wold sagde det her ..

COPENHAGEN, Denmark, November 9, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its interim financial results for the first nine months of 2016. Below is a summary of the financial performance for the period and business progress for the last quarter. The full interim report is attached as a PDF file and can be found on the company's website, www.bavarian-nordic.com.

Key highlights from the report

  • In October, the first Phase 2 clinical trial of MVA-BN RSV was initiated. The study will help to identify the optimal dose and schedule for a subsequent Phase 2b field efficacy study planned for initiation in 2017

  • In October, a Phase 2 trial investigating the combination of PROSTVAC and ipilimumab in patients with localized prostate cancer was initiated at the University of California, San Francisco

  • In September, Phase 1 results for the MVA-BN RSV vaccine were presented at the 10th International Respiratory Syncytial Virus Symposium

  • In September, Christopher Heery, M.D. was appointed Chief Medical Officer of Bavarian Nordic with immediate effect

  • In September, Janssen completed a submission for Emergency Use Assessment and Listing for the Ad26.ZEBOV/MVA-BN Filo prime-boost Ebola vaccine regimen to the World Health Organization

  • In August, Bavarian Nordic entered a drug supply agreement with Bristol-Myers Squibb, providing OPDIVO for the upcoming clinical trial of CV301 in NSCLC

  • The second planned interim analysis of the Phase 3 study of PROSTVAC occurred in July, confirming that the study should continue without modification. Final study data are anticipated in 2017 with a third interim analysis occurring prior to that

"We are very excited by the progress in Bavarian Nordic in 2016 to date. We have recently seen the initiation of two clinical trials for both PROSTVAC and RSV, and are currently screening patients for our lung cancer study combining CV301 and nivolumab. This not only progresses our pipeline, but also differentiates our profile in immuno-oncology and infectious diseases. We also recently had the pleasure of welcoming Christopher Heery as our new CMO. He will help us to continue this trajectory and to identify new opportunities for the Company going forward," said Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic.

Financial performance

Revenue for the nine month period ending September 30, 2016 was DKK 591 million, of which DKK 452 million was recognized in the third quarter. This is in line with the Company's expectations, as the majority of revenue relates to production of IMVAMUNE bulk drug substance produced for the U.S. Government, which primarily occurs in the second half of 2016. Thus approximately 40% of the year's revenue is expected to be recognized in the last quarter of 2016.

 

DKK million USD million

 

9m 2016 9m 2015 9m 2016 9m 2015
Revenue 591 703 88 105
EBIT (82) 2 (12) 0
Cash preparedness, period-end 1,647 1,618 247 242

Outlook for 2016

The Company maintains its financial expectations for 2016. For detailed assumptions, refer to the 2015 Annual Report. The expectations to cash preparedness at year-end were previously upgraded from DKK 1,300 million to DKK 1,900 million as result of a capital increase in April 2016.

2016E

DKK million USD million
Revenue 1,000 150
EBIT 0 0
Cash preparedness, year-end * 1,900 284

*

Cash preparedness includes cash, cash equivalents, investments in securities and the aggregate amount of undrawn credit lines.

Danish kroner (DKK) is the Company's functional currency. All USD figures provided above are based upon an assumed exchange rate of DKK 6.68 per 1.00 USD, which was the exchange rate as of September 30, 2016.

Conference call and webcast

The management of Bavarian Nordic will host a conference call today at 2 pm CET (8 am ET) to present the interim results followed by a Q&A session. Dial-in numbers for the conference call are: Denmark: +45 32 71 16 58, UK: +44 (0) 20 3427 1919, USA: +1 646 254 3363. Participant code is 1909904. A live and archived webcast of the call and relevant slides will be available at http://www.bavarian-nordic.com/investor/events.aspx?event=4532.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Ianvestor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Company Announcement no. 28 / 2016

2016-28-en

Interim Report Q3 2016


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil 1: 769710.pdf
Vedhæftet fil 2: 769711.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
25 jun
BAVA
Oven på en rigtig god fredag hvor vi nået 395 som er det højest kursniveau i nyere tid var det for m..
46
21 jun
BAVA
Men hvis man ikke efterrationalisere mere end, "nå", så er der da gode penge at hente i bankerne, ve..
27
23 jun
BAVA
Jeg kan se at nogle vælger at sælge lidt ud - det kan jeg for så vidt godt forstå - jeg vil dog uænd..
18
19 jun
BAVA
Nyhedsflowet fra Bavarian resten af 2017 bliver enormt spændende. Husk at det er Biotek og nyheder i..
17
21 jun
BAVA
Fra 0,77% til ca. 0,4%.   Derfor faldt den ikke tilbage i går. De har købt ca 120.000 aktier.   Det ..
15
21 jun
BAVA
Vrøvl er nu et godt ord, som vi bruger ALT for lidt i vores daglige kommunikation... Jeg kan også an..
10
25 jun
BAVA
Super indlæg igen, fra Enkommentar, og hvor er det dejligt at der er en som holder os ajour. Jeg lær..
8
25 jun
BAVA
Præcist, og det er jo ikke fordi vi ikke tænker på de medarbejdere som står uden arbejde. Alt andet ..
7
23 jun
BAVA
Måske nogen af jer husker, at jeg tidligt i foråret påstod at den ville være i 400 over sommeren. De..
7
23 jun
BAVA
Kære baronen. Prøv at læse meddelelsen igen. Man fyrer folk, fordi man har ændret produktionsmetoder..
7

Økonomisk planlægning

22-06-2017 09:52:24
Sponsoreret indhold:Alle har brug for en økonomisk plan. Men hvor skal du begynde? Vi forklarer hvordan i fire enkle trin.Selvom det kan virke overvældende at skulle planlægge sin økonomiske fremtid (der er så meget, der kan ske og så mange overvejelser), så behøver det ikke være stressende at lære at udarbejde en økonomisk plan, hvis du gør det rigtigt. Som alle store spørgsmål i livet er planlæg..

Aktier/tendens: Mærsk og Tryg kan komme i fokus

14-06-2017 08:08:45
A.P. Møller-Mærsk kan onsdag blive påvirket af kinesiske nøgletal og et løftet kursmål hos et større amerikansk finanshus, mens forsikringsselskabet Tryg kan blive presset af en sænket anbefaling af aktien af et italiensk finanshus.Overordnet set ventes det europæiske aktiemarked onsdag at åbne tæt på uændret, og mange investorer vil formentlig forholde sig afventende forud for resultatet af todag..

Carlsberg-konkurrent er klar til indrømmelser for britisk opkøb

13-06-2017 16:19:06
Den hollandske bryggerigigant Heineken, som blandt andet konkurrerer med Carlsberg, er parat til at komme med indrømmelser over for myndighederne i Storbritannien for at få lov til at overtage den britiske pubkæde Punch Taverns.Det skriver Bloomberg News, efter at de britiske konkurrencemyndigheder, Competition and Markets Authority (CMA), tidligere har advaret Heineken om, at selskabets overtagel..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Gode nyheder kan holde fokus på Novo i rolig åbning
2
Børsdebutant fortsætter massiv stigning på anden noteringsdag
3
Dansk musselmalet stel skaber stor gevinst - citat
4
Norwegian aflyser alle dagens flyafgange til og fra Aalborg - NY
5
Danske Bank går videre med finsk fusionsplan

Relaterede aktiekurser

Bavarian Nordic A/S 385,00 -2,5% Fald i aktiekurs
Bavarian Nordic DKK10 52,10 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. juni 2017 21:05:59
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170623.1 - EUROWEB6 - 2017-06-26 21:05:59 - 2017-06-26 21:05:59 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x